Li Wenbo, Kui Ling, Demetrios Tsirukis, Gong Xun, Tang Min
1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, China.
2Dana-Farber Cancer Institute, Harvard Medical School, United States.
Aging Dis. 2020 Oct 1;11(5):1260-1275. doi: 10.14336/AD.2020.0105. eCollection 2020 Oct.
Mitochondria are classically known to be cellular energy producers. Given the high-energy demanding nature of neurons in the brain, it is essential that the mitochondrial pool remains healthy and provides a continuous and efficient supply of energy. However, mitochondrial dysfunction is inevitable in aging and neurodegenerative diseases. In Alzheimer's disease (AD), neurons experience unbalanced homeostasis like damaged mitochondrial biogenesis and defective mitophagy, with the latter promoting the disease-defining amyloid β (Aβ) and p-Tau pathologies impaired mitophagy contributes to inflammation and the aggregation of Aβ and p-Tau-containing neurotoxic proteins. Interventions that restore defective mitophagy may, therefore, alleviate AD symptoms, pointing out the possibility of a novel therapy. This review aims to illustrate mitochondrial biology with a focus on mitophagy and propose strategies to treat AD while maintaining mitochondrial homeostasis.
传统上认为线粒体是细胞的能量生产者。鉴于大脑中神经元对能量的高需求特性,线粒体池保持健康并持续高效地提供能量至关重要。然而,线粒体功能障碍在衰老和神经退行性疾病中是不可避免的。在阿尔茨海默病(AD)中,神经元经历内稳态失衡,如受损的线粒体生物发生和有缺陷的线粒体自噬,后者会促进疾病标志性的淀粉样β(Aβ)和磷酸化tau蛋白(p-Tau)病变,受损的线粒体自噬会导致炎症以及含Aβ和p-Tau的神经毒性蛋白聚集。因此,恢复有缺陷的线粒体自噬的干预措施可能会缓解AD症状,这指出了一种新疗法的可能性。本综述旨在阐述线粒体生物学,重点关注线粒体自噬,并提出在维持线粒体稳态的同时治疗AD的策略。